glp-1 gray market Glucagon-like Peptide-1 (GLP-1) Agonists Size and Companies GLP-1 Medications: A Market on

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categoras 503A

Cost, Insurance Driving Move to Compounded Drugs Compounded GLP-1 medications are not approved by the FDA, and the agency issued a warning in June calling them potentially risky for patients. This hasnt stopped patients from switching to the unapproved drugs, and 35% of patients who took compounded GLP-1s left from a name brand drug, according to Gallup

12 Due to these potential side effects, medical supervision is crucial when initiating and maintaining treatment with semaglutide

*All peptide sales are nonrefundable and nonreturnable